Context Therapeutics is trading 5.13% up at $0.51, with the gain appearing to reflect trading volatility rather than a confirmed fundamental catalyst.
- No company-specific announcement dated August 20, 2026, was identified.
- The latest substantive release was the August 5 second-quarter update, which discussed CTIM-76 and CT-202 prioritization.
- Major indexes and biotech-sector sentiment are weaker.